Combined transarterial chemoembolization and tislelizumab for patients with unresectable hepatocellular carcinoma

doi:10.4240/wjgs.v16.i9.2829

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 16, Issue 9

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Supplementary Materials of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (1835)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-3) series, Tables (1-3) series.

Item

Count

PDF

HTML

1014

Figures (1-3)

209

Tables (1-3)

188

Sum=1451

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

Download

253

Sum=328

Sep 27, 2024 (publication date) through Apr 11, 2025

Times Cited of This Article

Times Cited (0)

Journal Information of This Article

Publication Name

World Journal of Gastrointestinal Surgery

ISSN

1948-9366

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Retrospective Study

World J Gastrointest Surg. Sep 27, 2024; 16(9): 2829-2841
Published online Sep 27, 2024. doi: 10.4240/wjgs.v16.i9.2829

Table 3 Adverse events

	n (%)
Elevated ALT
Grade 0-2	51 (91.07)
Grade ≥ 3	5 (8.93)
Elevated AST
Grade 0-2	50 (89.29)
Grade ≥ 3	6 (10.71)
Elevated total bilirubin
Grade 0-2	54 (96.43)
Grade ≥ 3	2 (3.57)
Rash
Grade 0-2	54 (96.43)
Grade ≥ 3	2 (3.57)
Itching
Grade 0-2	56 (100.00)
Grade ≥ 3	0
Vomiting
Grade 0-2	56 (100.00)
Grade ≥ 3	0
Diarrhea
Grade 0-2	56 (100.00)
Grade ≥ 3	0
Sensory abnormalities
Grade 0-2	56 (100.00)
Grade ≥ 3	0
Thyroiditis
Grade 0-2	56 (100.00)
Grade ≥ 3	0
Abdominal pain
Grade 0-2	56 (100.00)
Grade ≥ 3	0
Gastric ulcer
Grade 0-2	56 (100.00)
Grade ≥ 3	0
Bone marrow suppression
Grade 0-2	56 (100.00)
Grade ≥ 3	0

ALT: Alanine aminotransferase; AST: Aspartate aminotransferase.

Citation: Tan BB, Fu Y, Shao MH, Chen HL, Liu P, Fan C, Zhang H. Combined transarterial chemoembolization and tislelizumab for patients with unresectable hepatocellular carcinoma. World J Gastrointest Surg 2024; 16(9): 2829-2841
URL: https://www.wjgnet.com/1948-9366/full/v16/i9/2829.htm
DOI: https://dx.doi.org/10.4240/wjgs.v16.i9.2829